SCHEMBL24809408

SCHEMBL24809408

Cc1ccc(-c2cn(C(=O)NCCc3ccccc3)cn2)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 3/20 0.46
GAA P10253 2/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 4/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
APOBEC3A P31941 1/20 0.42
HSD17B10 Q99714 1/20 0.42
IDO1 P14902 1/20 0.41
MAPT P10636 1/20 0.41
TP53 P04637 1/20 0.41
NPC1 O15118 3/20 0.41
GSK3B P49841 1/20 0.41
NTRK1 P04629 1/20 0.41
YES1 P07947 1/20 0.41
PIM1 P11309 1/20 0.41
MAPK1 P28482 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24809404 0.87 ALDH1A1 (0.47) HIF1AKDM4EALDH1A1RAB9APOLB
SCHEMBL24810560 0.86 HIF1A (0.46) HIF1AKDM4EALDH1A1RAB9APOLB
SCHEMBL24811055 0.86 HIF1A (0.44) HIF1AGAAKDM4EALDH1A1RAB9A
SCHEMBL24810687 0.86 HIF1A (0.44) HIF1AKDM4ERAB9APOLBSMN1; SMN2
SCHEMBL29817737 0.85 CYP2C9 (0.54) HIF1AALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL24811030 0.85 CYP2C9 (0.54) HIF1AALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL24810556 0.84 HPGD (0.45) HIF1AKDM4EALDH1A1RAB9APOLB
SCHEMBL24810703 0.82 RAB9A (0.51) HIF1AGAAKDM4EALDH1A1RAB9A
SCHEMBL23132278 0.82 MCHR1 (0.45) HIF1AALDH1A1RAB9AMAPTTP53
SCHEMBL24810809 0.81 CNR1 (0.41) KDM4EALDH1A1RAB9ASMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114787135-A Substituted imidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 HIF1A 1983/4885GAA 2/4885KDM4E 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.